Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Authors:
Open Access
- 15 November 2022
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 7272-7274